If you want, I can:
The case study is a landmark document in the pharmaceutical industry, created by the CMC Biotech Working Group (including experts from Abbott, Amgen, Genentech, and Pfizer). It serves as a comprehensive educational tool to demonstrate how Quality by Design (QbD) principles from ICH Q8(R2), Q9, and Q10 can be applied to the complex lifecycle of a monoclonal antibody (mAb) . Core Framework and Objectives A Mab A Case Study In Bioprocess Development
pH, dissolved oxygen, and temperature were tightly controlled to maintain the desired glycosylation profile, as fluctuations can lead to undesired charge variants. 3. Downstream Process Development: Purification Strategy If you want, I can: The case study
A revealing case study from Syngene International for a cancer therapy mAb illustrates the importance of a methodical screening approach. Facing an aggressive and the need for high-titer clones, their team first generated stable pools, then narrowed down to monoclones through sorting and screening to select the top 10 candidates based on quality and titer. They then employed a Design of Experiments (DoE) approach, running 24 bioreactors and testing 22 experimental conditions across six key parameters , including clone selection, medium composition, feed types, and pH. This streamlined process reduced the number of experiments required and identified clones capable of industry-leading yields. When scaled up to 10-liter bioreactors, the process achieved a fourfold increase in titer to 7,200 mg/L in under a year, significantly boosting efficiency and lowering manufacturing costs. They then employed a Design of Experiments (DoE)
Process development moved from shake flasks to bench-top bioreactors, then to pilot-scale (e.g., 50 L to 500 L).
For mAb-X, we utilized . This is the workhorse of mAb purification because Protein A binds specifically to the Fc region of antibodies, ignoring almost everything else (host cell proteins, DNA, viruses).
The development of this mAb highlights the necessity of an integrated approach to bioprocessing. By focusing on robust upstream productivity and, in particular, leveraging tailored downstream chromatography (protein A and ion exchange), the project achieved a scalable process. The successful development relied heavily on: Early and precise .